Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
Conditions
Interventions
OB318 capsule
Locations
2
Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Taipei Medical University-Shuang Ho Hospital
Taipei, Taiwan
Start Date
September 11, 2020
Primary Completion Date
December 1, 2024
Completion Date
December 1, 2024
Last Updated
January 26, 2024
NCT06927297
NCT06760481
NCT04521413
NCT03363893
NCT05573724
NCT02439723
Lead Sponsor
Oneness Biotech Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions